Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
APYX 
Apyx Medical Inc (APYX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: APYX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.02% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 117.62M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 3 | Beta 1.46 | 52 Weeks Range 0.76 - 3.49 | Updated Date 10/16/2025 |
52 Weeks Range 0.76 - 3.49 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -37.11% | Operating Margin (TTM) -22.63% |
Management Effectiveness
Return on Assets (TTM) -12.45% | Return on Equity (TTM) -154.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 88819709 | Price to Sales(TTM) 2.53 |
Enterprise Value 88819709 | Price to Sales(TTM) 2.53 | ||
Enterprise Value to Revenue 1.91 | Enterprise Value to EBITDA -5.33 | Shares Outstanding 37819478 | Shares Floating 25697579 |
Shares Outstanding 37819478 | Shares Floating 25697579 | ||
Percent Insiders 14.55 | Percent Institutions 42.27 |
Upturn AI SWOT
Apyx Medical Inc
Company Overview
History and Background
Apyx Medical Inc., formerly Bovie Medical Corporation, was founded in 1921. The company has evolved from focusing on electrosurgical instruments to specializing in helium plasma technology for minimally invasive surgery and energy-based aesthetics. Significant milestones include the development of the Renuvion technology.
Core Business Areas
- Surgical: Develops and markets devices used in general surgery, bariatric surgery, and other surgical specialties. Focuses on the Renuvion technology for tissue coagulation and contraction.
- Cosmetic Surgery: Develops and markets devices, primarily Renuvion, used in cosmetic procedures such as skin resurfacing and body contouring.
Leadership and Structure
The leadership team includes Charlie Goodwin (CEO) and other key executives. The organizational structure is designed to support the development, manufacturing, and marketing of its energy-based technologies.
Top Products and Market Share
Key Offerings
- Renuvion: Renuvion is Apyx Medical's flagship product, utilizing helium plasma energy for tissue coagulation and contraction in cosmetic and surgical procedures. The competitor is InMode (INMD) with BodyTite and AccuTite devices.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulatory scrutiny, and increasing demand for minimally invasive procedures. The aesthetic market specifically sees rising demand.
Positioning
Apyx Medical is positioned as a player in the minimally invasive surgery and aesthetic markets with its Renuvion technology. Its competitive advantage lies in the unique helium plasma technology offering potentially faster recovery times.
Total Addressable Market (TAM)
The TAM for energy-based aesthetic devices is estimated to be in the billions of dollars. Apyx Medical is positioned to capture a portion of this market with Renuvion.
Upturn SWOT Analysis
Strengths
- Proprietary Renuvion technology
- Focus on minimally invasive procedures
- Growing presence in the aesthetic market
Weaknesses
- Dependence on Renuvion technology
- Smaller scale compared to larger competitors
- Regulatory risks associated with medical devices
Opportunities
- Expansion into new geographic markets
- Development of new applications for Renuvion
- Strategic partnerships or acquisitions
Threats
- Competition from established medical device companies
- Technological obsolescence
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- INMD
- BSX
- JNJ
- MRK
Competitive Landscape
Apyx Medical faces competition from larger, more established medical device companies. Its advantage lies in its specialized technology, but it needs to effectively compete with larger competitors with more resources and established distribution networks.
Growth Trajectory and Initiatives
Historical Growth: Apyx Medical's growth has been driven by the adoption of Renuvion technology in surgical and aesthetic procedures.
Future Projections: Future growth projections depend on analyst estimates, market trends, and company guidance. Expansion into new markets and new product development are factors.
Recent Initiatives: Recent initiatives may include new product launches, regulatory approvals, and strategic partnerships. This would be shown in the summary
Summary
Apyx Medical Inc. is a company with a unique helium plasma technology (Renuvion) that is gaining traction in the surgical and aesthetic markets. They need to carefully navigate regulatory approvals for medical devices while dealing with larger, more established competitors. The company must focus on expansion, innovation, and strategic partnerships to maximize shareholder returns. Currently it is projected for growth but must improve market share compared to competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Research Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered as investment advice. Investment decisions should be made based on individual circumstances and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apyx Medical Inc
Exchange NASDAQ | Headquaters Clearwater, FL, United States | ||
IPO Launch date 1987-01-01 | President, CEO & Director Mr. Charles D. Goodwin II | ||
Sector Healthcare | Industry Medical Devices | Full time employees 220 | Website https://apyxmedical.com |
Full time employees 220 | Website https://apyxmedical.com | ||
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company's helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.